CXC chemokine ligand‐13 promotes metastasis via CXCR5‐dependent signaling pathway in non‐small cell lung cancer

The CXC chemokine ligand‐13 (CXCL13) is a chemoattractant of B cells and has been implicated in the progression of many cancers. So far, CXCL13 and its related receptor CXCR5 have been proved to regulate cancer cell migration as well as tumour metastasis. However, the role of CXCL13‐CXCR5 axis in metastasis of lung cancer is still poorly understood. In this study, we found that CXCL13 and CXCR5 were commonly up‐regulated in lung cancer specimens compared with normal tissues among different cohorts. Our evidence showed that CXCL13 obviously promoted migration of lung cancer cells, and this effect was mediated by vascular cell adhesion molecule‐1 (VCAM‐1) expression. We also confirmed that CXCR5, the major receptor responsible for CXCL13 function, was required for CXCL13‐promoted cell migration. We also test the candidate components which are activated after CXCL13 treatment and found that phospholipase C‐β (PLCβ), protein kinase C‐α (PKCα) and c‐Src signalling pathways were involved in CXCL13‐promoted cell migration and VCAM‐1 expression in lung cancer cells. Finally, CXCL13 stimulated NF‐κB transcription factor in lung cancer cells, contributing to VCAM‐1 expression in translational level. These evidences propose a novel insight into lung cancer metastasis which is regulated by CXCL13.

[1]  D. Adah,et al.  CXCL13/CXCR5 signaling axis in cancer. , 2019, Life sciences.

[2]  J. Minna,et al.  LCE: an open web portal to explore gene expression and clinical associations in lung cancer , 2018, Oncogene.

[3]  Lily Wu,et al.  Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment , 2018, Precision clinical medicine.

[4]  G. Petroni,et al.  Mesothelium expression of vascular cell adhesion molecule‐1 (VCAM‐1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC) , 2017, Cancer.

[5]  D. Lu,et al.  MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma , 2017, Oncogene.

[6]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[7]  J. Blando,et al.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. , 2017, Cell reports.

[8]  Qing Xu,et al.  TNF-Alpha Promotes Invasion and Metastasis via NF-Kappa B Pathway in Oral Squamous Cell Carcinoma , 2017, Medical science monitor basic research.

[9]  M. R. Kim,et al.  A Human Antibody That Binds to the Sixth Ig-Like Domain of VCAM-1 Blocks Lung Cancer Cell Migration In Vitro , 2017, International journal of molecular sciences.

[10]  P. Gao,et al.  The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling , 2015, BioMed research international.

[11]  G. Bendas,et al.  Vascular cell adhesion molecule‐1 (VCAM‐1)—An increasing insight into its role in tumorigenicity and metastasis , 2015, International journal of cancer.

[12]  M. A. Afanasyeva,et al.  p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells , 2015, Scientific Reports.

[13]  L. Fu,et al.  CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway , 2015, Molecular and Cellular Biochemistry.

[14]  J. McCubrey,et al.  A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression , 2014, Oncotarget.

[15]  Shailesh Singh,et al.  Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma , 2014, International journal of oncology.

[16]  Inder M. Verma,et al.  NF-κB, an Active Player in Human Cancers , 2014, Cancer Immunology Research.

[17]  A. Dubrovska,et al.  Emerging targets in cancer management: role of the CXCL12/CXCR4 axis , 2013, OncoTargets and therapy.

[18]  T. Hwang,et al.  Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. , 2013, Carcinogenesis.

[19]  V. Malhotra,et al.  CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis , 2013, Breast Cancer Research and Treatment.

[20]  V. Beneš,et al.  Role of CXCL13 in asthma: novel therapeutic target. , 2012, Chest.

[21]  C. El-Haibi,et al.  Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. , 2012, Journal of proteomics & bioinformatics.

[22]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[23]  W. Muller,et al.  Mechanisms of leukocyte transendothelial migration. , 2011, Annual review of pathology.

[24]  Jian Zhang,et al.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression , 2010, Cancer and Metastasis Reviews.

[25]  P. Johnson,et al.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells , 2010, Molecular Cancer.

[26]  H. Pfister,et al.  The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. , 2009, Journal of neuroinflammation.

[27]  Chih-Hsin Tang,et al.  Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF‐κB pathways , 2009, The Prostate.

[28]  J. Van Damme,et al.  The role of CXC chemokines and their receptors in cancer. , 2008, Cancer letters.

[29]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[30]  C. Fraser.  G Protein–Coupled Receptor Connectivity to NF-κB in Inflammation and Cancer , 2008, International reviews of immunology.

[31]  W. Fu,et al.  Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. , 2008, Carcinogenesis.

[32]  V. Pistoia,et al.  CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow , 2008, Cancer Immunology, Immunotherapy.

[33]  E. Rozengurt.  Mitogenic signaling pathways induced by G protein‐coupled receptors , 2007, Journal of cellular physiology.

[34]  M. Keating,et al.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.

[35]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[36]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[37]  B. Sipos,et al.  The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. , 2006, Cancer research.

[38]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[39]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[40]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[41]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[42]  R. Strieter.  Chemokines: Not just leukocyte chemoattractants in the promotion of cancer , 2001, Nature Immunology.

[43]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[44]  R. Burgstahler,et al.  Regulation of expression of chemokine receptor BLR1/CXCR5 during B cell maturation. , 1999, Current topics in microbiology and immunology.

[45]  Jason G. Cyster,et al.  A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1 , 1998, Nature.

[46]  M. El-Sabban,et al.  Adhesion-mediated gap junctional communication between lung-metastatatic cancer cells and endothelium. , 1994, Invasion & metastasis.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.